Bayer seeks approval for blockbuster Xarelto to treat thromboembolism in children
Bayer added that it would submit an application to the European Medicines Agency for an extension of the Xarelto marketing authorisation. It did not give a timeframe.
FRANKFURT: Bayer will apply for approval to make its blockbuster blood thinner Xarelto available for treating children, the German company said on Monday, after a study showed strong efficacy and safety in children with thromboembolism.
The results of the phase III study were similar to those seen in previous studies with adults, the company said in a statement.
Bayer added that it would submit an application to the European Medicines Agency for an extension of the Xarelto marketing authorisation. It did not give a timeframe.
Xarelto is Bayer's best-selling drug and contributed 3.6 billion euros ($4.04 billion) in revenue to the group's pharmaceutical business last year.
Bayer jointly developed Xarelto with Johnson & Johnson's (JnJ) Janssen Pharmaceuticals, which sells the blood clot preventer under a licensing agreement in the United States.
J&J reported 2018 Xarelto sales of $2.47 billion. ($1 = 0.8916 euros)
Also Read: Bayer contested Glyphosate use will eventually end, says German Chancellor
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd